Characterization of Cationic Liposome Formulations Designed to Exhibit Extended Plasma Residence Times and Tumor Vasculature Targeting Properties
- 1 June 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmaceutical Sciences
- Vol. 99 (6), 2839-2853
- https://doi.org/10.1002/jps.22043
Abstract
No abstract availableThis publication has 48 references indexed in Scilit:
- Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and DoxorubicinClinical Cancer Research, 2008
- Importance of the Liposomal Cationic Lipid Content and Type in Tumor Vascular Targeting: Physicochemical Characterization and In Vitro Studies Using Human Primary and Transformed Endothelial CellsEndothelium, 2008
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's LymphomaClinical Cancer Research, 2006
- Applicability of anti-neovascular therapy to drug-resistant tumor: Suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycinInternational Journal of Pharmaceutics, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth SuppressionCancer Research, 2004
- Cancer Anti-angiogenic TherapyBiological & Pharmaceutical Bulletin, 2004
- Fundamental concepts of the angiogenic process.Current Molecular Medicine, 2003
- Liposome-mediated therapy of intracranial brain tumors in a rat model.Pharmaceutical Research, 1997
- Optimization of Transfection of Human Endothelial CellsEndothelium, 1997